Considering that BrCa is one of the most frequent malignancies, accounting for 11.7% of the total number of new cases diagnosed in 2020 [1,2] and that the role of HSPB2 in breast tumorigenesis or cancer progression has not yet been investigated, our study was focused on the potential prognostic significance of HSPB2 mRNA expression levels in BrCa patients. This evidence concerns the gene HSPB2 and cancer.